State of New Jersey Common Pension Fund D Decreases Position in Glaukos Co. (NYSE:GKOS)

State of New Jersey Common Pension Fund D cut its holdings in Glaukos Co. (NYSE:GKOS) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,418 shares of the medical instruments supplier’s stock after selling 87 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $2,530,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Assenagon Asset Management S.A. bought a new stake in shares of Glaukos in the 2nd quarter valued at about $6,832,000. Natixis bought a new stake in Glaukos in the first quarter valued at approximately $614,000. Vanguard Group Inc. boosted its stake in shares of Glaukos by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after purchasing an additional 72,159 shares during the period. UniSuper Management Pty Ltd bought a new position in shares of Glaukos in the first quarter worth approximately $913,000. Finally, Seven Eight Capital LP purchased a new position in shares of Glaukos in the second quarter worth $1,940,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of Glaukos stock opened at $143.21 on Thursday. The firm has a market capitalization of $7.90 billion, a P/E ratio of -47.42 and a beta of 1.02. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $145.84. The business has a fifty day simple moving average of $130.53 and a two-hundred day simple moving average of $121.82.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. During the same period in the previous year, the firm posted ($0.50) EPS. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year. On average, equities analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,275 shares of company stock valued at $1,354,967. Insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GKOS. BTIG Research raised their price target on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. JPMorgan Chase & Co. boosted their price target on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Stifel Nicolaus increased their price objective on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Truist Financial boosted their target price on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Wells Fargo & Company raised their price target on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.